-- 據 Euroz Hartleys 在 4 月 24 日發布的一份報告中稱，Alkane Resources (ASX:ALK) 在 3 月的季度中實現了顯著的產量超預期，這主要得益於其所有礦區礦石品位均高於預期，新南威爾士州 Tomingley 金礦項目的處理量略有預期，以及瑞典礦山的回收率 提高金。 Euroz Hartleys 表示，該公司公佈的合併黃金當量產量約為 45,800 盎司，創下集團早期產量紀錄。 這家股票研究公司指出，Alkane Resources 除了 2,000 萬澳元的設備融資外，目前沒有其他債務。此外，該公司還擁有一筆尚未提取的 1.1 億澳元循環信貸額度和一筆 4,000 萬澳元的或有工具信貸額度，這為其快速把握新興機會提供了流動性。 該公司預計將超過其2026財年黃金當量產量指引的中位數，即每盎司黃金當量產量16萬至17.5萬盎司，綜合維持成本為每盎司2600至2900澳元。然而，Euroz Hartleys預計，由於集團整體礦石品位下降，截至6月的三個月內，產量將比去年同期放緩。 Euroz Hartleys維持對該公司的「買入」評級，並將目標價從2.50澳元上調至2.53澳元。
Related Articles
Asia
Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%
Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.
$ASX:ONE
Asia
Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low
Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.
$ASX:PAR
Asia
Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%
Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.
$SHA:600703